Tonix Pharmaceuticals Holding Corp. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TNXP Nasdaq 2830 www.tonixpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) - Jun 29th, 2026 5:25 am
Qualcomm upgrade, Intel initiation among today's top calls on Wall Street - Jun 25th, 2026 7:34 am
We're Keeping An Eye On Tonix Pharmaceuticals Holding's (NASDAQ:TNXP) Cash Burn Rate - Jun 13th, 2026 6:43 am
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 - Jun 11th, 2026 5:00 am
Why Is TNXP Stock Rising Today? - Jun 8th, 2026 7:46 am
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives - Jun 8th, 2026 5:00 am
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting - May 28th, 2026 2:30 pm
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology - May 27th, 2026 5:00 am
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting - May 26th, 2026 5:00 am
TNXP: Secures Commercial Payer Coverage for Tonmya® to Provide Access for ~35 Million U.S. Patients - May 20th, 2026 8:25 am
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 - May 14th, 2026 5:00 am
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May - May 12th, 2026 2:30 pm
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights - May 11th, 2026 2:30 pm
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients - May 6th, 2026 5:00 am
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at Johns Hopkins University - Apr 29th, 2026 5:00 am
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 - Apr 23rd, 2026 5:00 am
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - Apr 15th, 2026 5:00 am
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - Mar 31st, 2026 5:00 am
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Mar 26th, 2026 5:00 am
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - Mar 23rd, 2026 2:32 pm